Shots:

• The discontinuation of a clinical program is based on an interim analysis for futility in P-II IGUANA study which demonstrated low probability to meet 1EPs i.e- the percentage change in EASI score
• The clinical development program of MOR106 includes two P-II IGUANA & GECKO studies- P-I bridging study for SC formulation and Japanese ethno-bridging study. All the studies evaluating MOR106 in AD will be terminated
• MOR106 is a mAb targeting IL-17C- jointly discovered by Galapagos and MorphoSys. In July’2019- Galapagos and MorphoSys signed an exclusive WW development and commercialization agreement with Novartis for MOR106

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Hin.be